Cargando…

Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging

Mapping tumor hypoxia is a great challenge in positron emission tomography (PET) imaging as the precise functional information of the biological processes is needed for many effective therapeutic strategies. Tumor hypoxia has been widely reported as a poor prognostic indicator and is often associate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colombié, Mathilde, Gouard, Sébastien, Frindel, Mathieu, Vidal, Aurélien, Chérel, Michel, Kraeber-Bodéré, Françoise, Rousseau, Caroline, Bourgeois, Mickaël
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547458/ https://www.ncbi.nlm.nih.gov/pubmed/26380261 http://dx.doi.org/10.3389/fmed.2015.00058

Ejemplares similares

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

Assessment of hypoxia and oxidative-related changes in a lung-derived brain metastasis model by [(64)Cu][Cu(ATSM)] PET and proteomic studies
por: Fantin, Jade, et al.
Publicado: (2023)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma
por: Bailly, Clément, et al.
Publicado: (2018)

What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between (89)Zr- and (64)Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model
por: Bailly, Clément, et al.
Publicado: (2019)

Tissue acidosis does not mediate the hypoxia selectivity of [(64)Cu][Cu(ATSM)] in the isolated perfused rat heart
por: Baark, Friedrich, et al.
Publicado: (2019)

Pre-clinical Positron Emission Tomography Reconstruction Algorithm Effect on Cu-64 ATSM Lesion Hypoxia
por: Sanghera, Bal, et al.
Publicado: (2016)

Impact of [(64)Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report
por: Gangemi, Vincenzo, et al.
Publicado: (2019)

Immuno-PET: Design options and clinical proof-of-concept
por: Lugat, Alexandre, et al.
Publicado: (2022)

Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture
por: Bailly, Clément, et al.
Publicado: (2019)

64Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model
por: Park, Seong Yong, et al.
Publicado: (2015)

Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer
por: Mathieu, Cédric, et al.
Publicado: (2015)

Hypoxia imaging and theranostic potential of [(64)Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms
por: Liu, Tengzhi, et al.
Publicado: (2020)

Pharmacokinetic Analysis of (64)Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice
por: Li, Fan, et al.
Publicado: (2015)

Modification of intracellular glutathione status does not change the cardiac trapping of (64)Cu(ATSM)
por: Shaughnessy, Fiona, et al.
Publicado: (2014)

(64)Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts
por: Yoshii, Yukie, et al.
Publicado: (2017)

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

Validation of (64)Cu-ATSM damaging DNA via high-LET Auger electron emission
por: McMillan, Dayton D., et al.
Publicado: (2015)

(64)Cu-ATSM Predicts Efficacy of Carbon Ion Radiotherapy Associated with Cellular Antioxidant Capacity
por: Nachankar, Ankita, et al.
Publicado: (2021)

Evaluation of hypoxia in a feline model of head and neck cancer using (64)Cu-ATSM positron emission tomography/computed tomography
por: Ballegeer, Elizabeth A, et al.
Publicado: (2013)

ET-7 EVALUATION OF HYPOXIA-TARGETING RADIOPHARMACEUTICAL(64)CU-ATSM FOR PET MONITORING WITH LOCAL THERAPY IN HIGH-GRADE GLIOMA MODEL
por: Yoshii, Yukie, et al.
Publicado: (2022)

Advantages of systematic trunk SPECT/CT to planar bone scan (PBS) in more than 300 patients with breast or prostate cancer
por: Fleury, Vincent, et al.
Publicado: (2018)

Potential for Nuclear Medicine Therapy for Glioblastoma Treatment
por: Bailly, Clément, et al.
Publicado: (2019)

Cu(II)(atsm) Attenuates Neuroinflammation
por: Choo, Xin Yi, et al.
Publicado: (2018)

Micro Regional Heterogeneity of (64)Cu-ATSM and (18)F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis
por: Zornhagen, Kamilla Westarp, et al.
Publicado: (2015)

Innovative radiopharmaceuticals in oncology and neurology
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2017)

Hypoxia Imaging Using PET and SPECT: The Effects of Anesthetic and Carrier Gas on [(64)Cu]-ATSM, [(99m)Tc]-HL91 and [(18)F]-FMISO Tumor Hypoxia Accumulation
por: Kersemans, Veerle, et al.
Publicado: (2011)

Cerebral Oxidative Stress in Early Alzheimer’s Disease Evaluated by (64)Cu-ATSM PET/MRI: A Preliminary Study
por: Okazawa, Hidehiko, et al.
Publicado: (2022)

Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up
por: Rusu, Daniela, et al.
Publicado: (2015)

ImmunoPET to help stratify patients for targeted therapies and to improve drug development
por: Kraeber-Bodere, Françoise, et al.
Publicado: (2016)

Multiple Administrations of (64)Cu-ATSM as a Novel Therapeutic Option for Glioblastoma: a Translational Study Using Mice with Xenografts
por: Yoshii, Yukie, et al.
Publicado: (2017)

Feasibility of Renal Blood Flow Measurement Using (64)Cu-ATSM PET/MRI: A Quantitative PET and MRI Study
por: Nishikawa, Yudai, et al.
Publicado: (2023)

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors
por: Rousseau, Caroline, et al.
Publicado: (2011)

PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients
por: Bailly, Clément, et al.
Publicado: (2017)

ARRONAX Cyclotron: Setting up of In-House Hospital Radiopharmacy
por: Vidal, Aurelien, et al.
Publicado: (2020)

Use of Molecular Imaging Markers of Glycolysis, Hypoxia and Proliferation ((18)F-FDG, (64)Cu-ATSM and (18)F-FLT) in a Dog with Fibrosarcoma: The Importance of Individualized Treatment Planning and Monitoring
por: Zornhagen, Kamilla Westarp, et al.
Publicado: (2015)

ImmunoPET in Multiple Myeloma—What? So What? Now What?
por: Bailly, Clément, et al.
Publicado: (2020)

Cellular Uptake of the ATSM−Cu(II) Complex under Hypoxic Conditions
por: Walke, Gulshan R., et al.
Publicado: (2021)

Immuno-PET for Clinical Theranostic Approaches
por: Bailly, Clément, et al.
Publicado: (2016)

CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits
por: Vieira, Fernando G., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kl7haqsmj4l01s555pfntu4ns5